FDA says 32mg dose of GSK drug Zofran will no longer be marketed

theflyonthewall.com

The U.S. Food and Drug Administration is notifying health care professionals that the 32 mg, single intravenous dose of GlaxoSmithKline's (GSK) antinausea drug Zofran will no longer be marketed because of the potential for serious cardiac risks. This dose has been removed from the Zofran drug label.

View Comments